Even though there is no standard targeted systemic therapy for TN tumors [3,4,8], such as trastuzumab for Her2+ tumors [9], the rates of complete clinical response and complete pathological response (pCR) to neoadjuvant chemotherapies are also similar in both Her2+ and TN breast cancer [10-12]. The gene discussed is ERBB2; the disease is breast carcinoma.